These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22663012)

  • 41. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.
    Leonowens C; Pendry C; Bauman J; Young GC; Ho M; Henriquez F; Fang L; Morrison RA; Orford K; Ouellet D
    Br J Clin Pharmacol; 2014 Sep; 78(3):524-32. PubMed ID: 24606567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
    Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
    Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Management of Multifocal Atrial Tachycardia in Noonan's Syndrome With MEK1/2 Inhibitor Trametinib.
    Meisner JK; Bradley DJ; Russell MW
    Circ Genom Precis Med; 2021 Oct; 14(5):e003327. PubMed ID: 34463117
    [No Abstract]   [Full Text] [Related]  

  • 45. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent.
    Leonard JT; Raess PW; Dunlap J; Hayes-Lattin B; Tyner JW; Traer E
    J Hematol Oncol; 2016 Mar; 9():31. PubMed ID: 27036514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T; Li C; Wang H
    Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
    Levine O; Devji T; Xie F
    Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
    [No Abstract]   [Full Text] [Related]  

  • 53. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.
    Gounder MM; Solit DB; Tap WD
    N Engl J Med; 2018 May; 378(20):1945-1947. PubMed ID: 29768143
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeting of MEK in lung cancer therapeutics.
    Heigener DF; Gandara DR; Reck M
    Lancet Respir Med; 2015 Apr; 3(4):319-27. PubMed ID: 25801412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
    Postow MA
    Clin Adv Hematol Oncol; 2018 May; 16(5):353-355. PubMed ID: 29851931
    [No Abstract]   [Full Text] [Related]  

  • 56. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
    [No Abstract]   [Full Text] [Related]  

  • 58. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
    Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
    Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experience with trametinib in a pediatric patient with MAP2K1-related cervicofacial arteriovenous malformation.
    Swaminathan N; Smith JD; Parmar HA; Gemmete JJ; Pipe SW; Zopf DA
    Pediatr Blood Cancer; 2024 Nov; 71(11):e31298. PubMed ID: 39189671
    [No Abstract]   [Full Text] [Related]  

  • 60. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
    Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
    Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.